Cargando…

Data on the oral CRTh2 antagonist QAW039 (fevipiprant) in patients with uncontrolled allergic asthma

This article contains data on clinical endpoints (Peak Flow Expiratory Rate, fractional exhaled nitric oxide and total IgE serum levels) and plasma pharmacokinetic parameters concerning the use of the oral CRTh2 antagonist QAW039 (fevipiprant) in mild to moderate asthma patients. Information on expe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Erpenbeck, Veit J., Popov, Todor A., Miller, David, Weinstein, Steven F., Spector, Sheldon, Magnusson, Baldur, Osuntokun, Wande, Goldsmith, Paul, Weiss, Markus, Beier, Jutta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2016
Materias:	Data Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021787/ https://www.ncbi.nlm.nih.gov/pubmed/27656673 http://dx.doi.org/10.1016/j.dib.2016.08.039

Ejemplares similares

Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo‐Controlled Studies in Healthy Volunteers
por: Erpenbeck, Veit J., et al.
Publicado: (2016)

Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date
por: Kao, Christina C, et al.
Publicado: (2019)

Efficacy and Safety of Fevipiprant in Asthma: A Review and Meta-Analysis
por: Jahangir, Abdullah, et al.
Publicado: (2022)

Efficacy and safety of fevipiprant in patients with uncontrolled asthma: Two replicate, phase 3, randomised, double-blind, placebo-controlled trials (ZEAL-1 and ZEAL-2)
por: Castro, Mario, et al.
Publicado: (2021)

CRTH2 expression on T cells in asthma
por: Mutalithas, K, et al.
Publicado: (2010)

CRTH2: a potential target for the treatment of organ fibrosis: CRTH2 is a potential target for organ fibrosis
por: Fan, Sisi, et al.
Publicado: (2022)

CRTH2 antagonists in asthma: current perspectives
por: Singh, Dave, et al.
Publicado: (2017)

CRTH2 in Pulmonary Fibrosis: Friend or Foe?
por: He, Chao, et al.
Publicado: (2022)

Long-term safety and exploratory efficacy of fevipiprant in patients with inadequately controlled asthma: the SPIRIT randomised clinical trial
por: Maspero, Jorge, et al.
Publicado: (2021)

Blockade of thymic stromal lymphopoietin and CRTH2 attenuates airway inflammation in a murine model of allergic asthma
por: Lee, Hea Yon, et al.
Publicado: (2020)

The therapeutic potential of CRTH2/DP2 beyond allergy and asthma
por: Jandl, Katharina, et al.
Publicado: (2017)

Title unknown, CERN-ALEPH-PHYSIC-96-039
por: CERN. Geneva. ALEPH
Publicado: (1996)

P01-039 – Autonomic functions in children with FMF
por: Fidanci, K, et al.
Publicado: (2013)

An Analysis of Artificial Pneumothorax Treatment in 1,039 Patients
por: Frimodt-Möller, C., et al.
Publicado: (1937)

SUN-039 Estradiol Dose and Concentrations in Transfeminine Individuals
por: Nolan, Brendan J, et al.
Publicado: (2020)

LBODP039 Glycogenic Hepatopathy- An Underrecognized Complication Of Diabetes
por: Chamakkala, Tess, et al.
Publicado: (2022)

Disposition and Metabolism of Setipiprant, a Selective Oral CRTH2 Antagonist, in Humans
por: Hoch, Matthias, et al.
Publicado: (2013)

Modulation of CRTh2 expression on allergen‐specific T cells following peptide immunotherapy
por: Rudulier, Christopher D., et al.
Publicado: (2019)

P039 Genioglossus motor control during mandibular advancement.
por: Dawson, A, et al.
Publicado: (2023)

Targeting the PGD(2)/CRTH2/DP1 Signaling Pathway in Asthma and Allergic Disease: Current Status and Future Perspectives
por: Kupczyk, Maciej, et al.
Publicado: (2017)

Inhibition of CRTH2-mediated Th2 activation attenuates pulmonary hypertension in mice
por: Chen, Guilin, et al.
Publicado: (2018)

AB039. Metabolic syndrome/cardiovascular disease and erectile dysfunction (ED)
por: Xing, Junping
Publicado: (2015)

AB039. The application of RigiScan in the diagnosis and treatment of erectile dysfunction
por: Zhang, Xiansheng
Publicado: (2018)

SUN-039 Characterization of Human Adrenal Steroidogenesis during Fetal Development
por: Melau, Cecilie, et al.
Publicado: (2019)

P.039 Is replacement of tAN cells in routine viral culture possible?
por: Damen, M., et al.
Publicado: (2009)

PSAT039 Concomitant Primary and Secondary Adrenal Insufficiency in the Setting of Immunotherapy
por: Estrada, Kathleen, et al.
Publicado: (2022)

FRI039 Endothelial Dysfunction Is Associated With Adiponectin And Leptin In Adolescents With PCOS
por: Gavryutina, Irina, et al.
Publicado: (2023)

Cross-talk of PGD(2) receptors: the DP receptor modulates signaling and trafficking of CRTH2
por: Sedej, Miriam, et al.
Publicado: (2010)

Chemoattractant Receptor Homologous to the T Helper 2 Cell (CRTH2) Is Not Expressed in Human Amniocytes and Myocytes
por: Sykes, Lynne, et al.
Publicado: (2012)

Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma
por: Kuna, Piotr, et al.
Publicado: (2016)

CRTH2 promotes endoplasmic reticulum stress‐induced cardiomyocyte apoptosis through m‐calpain
por: Zuo, Shengkai, et al.
Publicado: (2018)

Activation of Th2 cells downregulates CRTh2 through an NFAT1 mediated mechanism
por: MacLean Scott, Emily, et al.
Publicado: (2018)

The CRTh2 polymorphism rs533116 G > A associates with asthma severity in older females
por: Shrestha Palikhe, Nami, et al.
Publicado: (2022)

Over-expression of CRTH2 indicates eosinophilic inflammation and poor prognosis in recurrent nasal polyps
por: Chen, Wenhui, et al.
Publicado: (2022)

PW01-039 – Long-term efficacy of anakinra in SoJIA patients
por: Naselli, A, et al.
Publicado: (2013)

PW02-039 - Long-term anakinra treatment in CAPS: a metaanalys
por: Leinonen, M, et al.
Publicado: (2013)

Generation of KCL039 clinical grade human embryonic stem cell line
por: Devito, Liani, et al.
Publicado: (2016)

T.03.9 MUTYH-ASSOCIATED POLYPOSIS: IS TIME TO CHANGE UPPER GI SURVEILLANCE?
por: Sanchez-Mete, L., et al.
Publicado: (2022)

ODP039 Giant Cystic Pheochromocytoma and GIST in a Patient With NF-1
por: Inkollu, Sindhura, et al.
Publicado: (2022)

Application of the CDK9 inhibitor FIT-039 for the treatment of KSHV-associated malignancy
por: Sakamoto, Tetsunori, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ajk8r55dgg38kojd7hmme3sphg